SEC For	m 4																	
FORM 4 UNITED STAT				ATE	TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								RSHIP OMB Number: 3235-0287 Estimated average burden hours per response: 0.5					
1. Name and Address of Reporting Person <sup>*</sup> Smither John W				2.	Issuer	Name ar	nd Tic	ker or Trading trapeutics	g Symbol	(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				ner			
	(Last) (First) (Middle) C/O EFFECTOR THERAPEUTICS, INC. 142 NORTH CEDROS AVENUE, SUITE B				3. Date of Earliest Transaction (Month/Day/Year) 01/20/2023							Officer (give title Other (specify below) below)						
(Street) SOLANA BEACH CA 92075				4.	If Ame	ndment, I	Date	of Original Fil	ed (Month/D	Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(S	-	(Zip) Die I - Non-Der	ivativ	e Se	curities	s Ac	quired, D	isposed	of, or Be	neficial	ly Owned						
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					ear) i	2A. Deemed Execution Date, f any Month/Day/Yea		Code (Ins	on Dispose			Beneficia	s ally ollowing	6. Own Form: I (D) or I (I) (Inst	Direct o ndirect E r. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V		(0)		Transact (Instr. 3 a	ion(s)			məti. 4j		
		-	Table II - Deriv (e.g.,					uired, Dis , options				Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	ly E	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							
Stock Option (Right to Buy)	<b>\$</b> 0.4688	01/20/2023		A		36,875		(1)	01/19/2033	Common Stock	36,875	\$0.00	36,875	5	D			

Explanation of Responses:

1. The shares subject to the option will vest in substantially equal monthly installments over 12 months, commencing on January 20, 2023, subject to the Reporting Person's continued service with the Issuer through each vesting date.

## Remarks:

/s/ Michael Byrnes, Attorney-	01/2
in-Fact for John W. Smither	01/2

\*\* Signature of Reporting Person

24/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.